Business Context and Reporting Period
Daré Bioscience, Inc. filed a Form 8-K Current Report on May 28, 2018. The registrant is a Delaware corporation headquartered in La Jolla, California, and is classified as an emerging growth company.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance amendments.
Material Changes
Effective May 28, 2018, the Board of Directors approved an amendment to the Company's Second Amended and Restated By-laws. The amendment grants the Board sole discretion to determine that any stockholder meeting shall not be held at a physical location and may instead be conducted solely by means of remote communication, as authorized by Section 211(a)(2) of the Delaware General Corporation Law.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the procedural change regarding the venue of stockholder meetings.
Key Facts for Investor Verification
- The Board now has the authority to hold stockholder meetings entirely via remote communication without a physical location.
- The amendment to the By-laws became effective on May 28, 2018.
- The full text of the amended By-laws is attached as Exhibit 3.1 to this report.
- No financial performance data is disclosed in this specific filing.